Additional Cost Management Strategies Organizations exploring GLP-1 coverage are also considering targeted cost-control measures, including: Setting clinical qualification standards based on BMI and related conditions Establishing duration or lifetime coverage limits where allowed Adjusting copays or deductibles for obesity-related medications Favoring lower-utilization or lower-cost therapeutic alternatives within the formulary Evaluating alternative treatments such as bariatric surgery, which may produce durable outcomes at comparable costs to a year of medication therapy These strategies allow employers to maintain access while aligning coverage with financial objectives
By Wednesday morning, something had changed
Dulaglutide (Trulicity) is sometimes a bit lower, around $850 to $1,200 per month
June 22, 2015
Systematic Review Registration: PROSPERO identifier: CRD42021289121
As The Guardian reports, The Danish drugmakers market value has soared over the past year, making it the most valuable company in Europe, on the back of the success of its obesity and diabetes injections Wegovy and Ozempic, used by celebrities including Elon Musk and Oprah Winfrey
:max_bytes(150000):strip_icc()/Wegovy-pill-pic-590ed53ed3304ba8b2388f9d78886dae.png)
